Elevated expression of AGGF1 predicts poor prognosis and promotes the metastasis of colorectal cancer
Background: Angiogenic factor with G-patch and FHA domains 1 (AGGF1) can promote angiogenesis and increasing evidence has highlighted the important roles of AGGF1 in tumorigenesis. However, the differential expression as well as the biological functions of AGGF1 in colorectal cancer (CRC) remain to be established. The purpose of the present study is therefore to identify the effect of AGGF1 on prognosis and metastasis in CRC patients. Methods: The expression level of AGGF1 in CRC was examined by qPCR, western blot and immunohistochemistry in a tissue microarray containing 101 CRC specimens and paired normal mucosae. And the effect of AGGF1 on CRC cell malignance was investigated in our established stable AGGF1 upregulated and knockdown CRC cell lines. Results: The expression level of AGGF1 in CRC tissue was not significantly different to that in adjacent normal mucosa at the mRNA level. However, at the protein level, AGGF1 expression in CRC tissues was significantly higher than in paired normal mucosa, which showed a clear association with TNM stage, AJCC stage, vascular invasion, and differentiation. Further, we revealed an apparent correlation between AGGF1 expression and poorer disease-free survival and overall survival of CRC patients. In addition, we discovered that AGGF1 significantly promoted CRC cell wound healing, migration, and invasion in vitro and distant metastasis in vivo. Conclusions: Our study demonstrates the aberrant expression of AGGF1 in CRC and provides a basis on which to explore the application of AGGF1 as a novel prognostic biomarker as well as a therapeutic target for CRC patients, especially for CRC patients with distant metastasis.
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
On 27 Dec, 2019
On 17 Dec, 2019
On 17 Dec, 2019
On 12 Dec, 2019
On 10 Dec, 2019
On 09 Dec, 2019
On 09 Dec, 2019
Posted 02 Dec, 2019
On 05 Dec, 2019
Received 04 Dec, 2019
On 22 Nov, 2019
Invitations sent on 21 Nov, 2019
On 21 Nov, 2019
On 20 Nov, 2019
On 19 Nov, 2019
On 19 Nov, 2019
On 06 Nov, 2019
On 27 Oct, 2019
On 25 Oct, 2019
On 23 Oct, 2019
Invitations sent on 22 Oct, 2019
On 21 Oct, 2019
On 20 Oct, 2019
On 20 Oct, 2019
On 03 Oct, 2019
Received 02 Oct, 2019
Received 26 Sep, 2019
Received 26 Sep, 2019
On 14 Sep, 2019
On 13 Sep, 2019
On 10 Sep, 2019
On 10 Sep, 2019
On 10 Sep, 2019
Invitations sent on 10 Sep, 2019
On 10 Sep, 2019
On 28 Aug, 2019
Elevated expression of AGGF1 predicts poor prognosis and promotes the metastasis of colorectal cancer
On 27 Dec, 2019
On 17 Dec, 2019
On 17 Dec, 2019
On 12 Dec, 2019
On 10 Dec, 2019
On 09 Dec, 2019
On 09 Dec, 2019
Posted 02 Dec, 2019
On 05 Dec, 2019
Received 04 Dec, 2019
On 22 Nov, 2019
Invitations sent on 21 Nov, 2019
On 21 Nov, 2019
On 20 Nov, 2019
On 19 Nov, 2019
On 19 Nov, 2019
On 06 Nov, 2019
On 27 Oct, 2019
On 25 Oct, 2019
On 23 Oct, 2019
Invitations sent on 22 Oct, 2019
On 21 Oct, 2019
On 20 Oct, 2019
On 20 Oct, 2019
On 03 Oct, 2019
Received 02 Oct, 2019
Received 26 Sep, 2019
Received 26 Sep, 2019
On 14 Sep, 2019
On 13 Sep, 2019
On 10 Sep, 2019
On 10 Sep, 2019
On 10 Sep, 2019
Invitations sent on 10 Sep, 2019
On 10 Sep, 2019
On 28 Aug, 2019
Background: Angiogenic factor with G-patch and FHA domains 1 (AGGF1) can promote angiogenesis and increasing evidence has highlighted the important roles of AGGF1 in tumorigenesis. However, the differential expression as well as the biological functions of AGGF1 in colorectal cancer (CRC) remain to be established. The purpose of the present study is therefore to identify the effect of AGGF1 on prognosis and metastasis in CRC patients. Methods: The expression level of AGGF1 in CRC was examined by qPCR, western blot and immunohistochemistry in a tissue microarray containing 101 CRC specimens and paired normal mucosae. And the effect of AGGF1 on CRC cell malignance was investigated in our established stable AGGF1 upregulated and knockdown CRC cell lines. Results: The expression level of AGGF1 in CRC tissue was not significantly different to that in adjacent normal mucosa at the mRNA level. However, at the protein level, AGGF1 expression in CRC tissues was significantly higher than in paired normal mucosa, which showed a clear association with TNM stage, AJCC stage, vascular invasion, and differentiation. Further, we revealed an apparent correlation between AGGF1 expression and poorer disease-free survival and overall survival of CRC patients. In addition, we discovered that AGGF1 significantly promoted CRC cell wound healing, migration, and invasion in vitro and distant metastasis in vivo. Conclusions: Our study demonstrates the aberrant expression of AGGF1 in CRC and provides a basis on which to explore the application of AGGF1 as a novel prognostic biomarker as well as a therapeutic target for CRC patients, especially for CRC patients with distant metastasis.
Figure 1
Figure 2
Figure 3